Literature DB >> 2674763

Chronic inhibition of hypothalamic-pituitary-ovarian axis and body weight gain by brain-directed delivery of estradiol-17 beta in female rats.

D K Sarkar1, S J Friedman, S S Yen, S A Frautschy.   

Abstract

The effect of preferential delivery of estradiol (E2) into the brain on both the hypothalamic-pituitary-ovarian axis and weight gain was studied in female rats. When E2 was coupled to a lipoidal dihydropyridine-pyridinium carrier, the resulting carrier E2 complex (CE), upon a single intravenous administration to cycling female rats, caused a dose-dependent inhibition of ovulation which lasted 3 times longer than with uncoupled E2. The dose of CE that delayed ovulation for 4 days was one twentieth the amount of E2 needed to produce the same effect. Studies in ovariectomized (OVEX) rats indicated that the prolonged ovulation-blocking action of CE appeared to be related to a sustained storage and release of E2 in the brain, which in turn suppressed the release of hypothalamic luteinizing hormone-releasing hormone (LHRH) and pituitary luteinizing hormone (LH). Upon single intravenous administration in pubertal female rats, CE caused a dose-dependent reduction of body weight gain for a minimum period of 28 days. The inhibitory action of CE on body weight gain was more potent and longer lasting than that of E2 in pubertal rats. When administered in OVEX rats, CE produced a loss of body weight that lasted significantly longer than that produced by uncoupled E2 in these rats. These results suggest that the biological action of E2 can be potentiated by this novel chemical delivery system.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2674763      PMCID: PMC4352090          DOI: 10.1159/000125223

Source DB:  PubMed          Journal:  Neuroendocrinology        ISSN: 0028-3835            Impact factor:   4.914


  33 in total

1.  Improved delivery through biological membranes. 32. Synthesis and biological activity of brain-targeted delivery systems for various estradiol derivatives.

Authors:  M E Brewster; K S Estes; N Bodor
Journal:  J Med Chem       Date:  1988-01       Impact factor: 7.446

2.  Progesterone-estrogen interactions in the control of activity-wheel running in the female rat.

Authors:  W I Rodier
Journal:  J Comp Physiol Psychol       Date:  1971-03

Review 3.  Steroid hormones: humoral signals which alter brain cell properties and functions.

Authors:  B S McEwen; A Biegon; P G Davis; L C Krey; V N Luine; M Y McGinnis; C M Paden; B Parsons; T C Rainbow
Journal:  Recent Prog Horm Res       Date:  1982

4.  The premenstrual syndrome. Effects of "medical ovariectomy".

Authors:  K N Muse; N S Cetel; L A Futterman; S C Yen
Journal:  N Engl J Med       Date:  1984-11-22       Impact factor: 91.245

Review 5.  Does LHRH meet the criteria for a hypothalamic releasing factor?

Authors:  D K Sarkar
Journal:  Psychoneuroendocrinology       Date:  1983       Impact factor: 4.905

6.  Pharmacokinetic and pharmacological features of oestradiol valerate.

Authors:  B Düsterberg; Y Nishino
Journal:  Maturitas       Date:  1982-12       Impact factor: 4.342

7.  The sites of action of ovarian steroids in the regulation of LH secretion.

Authors:  R L Goodman; E Knobil
Journal:  Neuroendocrinology       Date:  1981-01       Impact factor: 4.914

8.  Hyperprolactinemia decreases the luteinizing hormone-releasing hormone concentration in pituitary portal plasma: a possible role for beta-endorphin as a mediator.

Authors:  D K Sarkar; S S Yen
Journal:  Endocrinology       Date:  1985-05       Impact factor: 4.736

9.  Mechanism of the first spontaneous gonadotrophin surge and that induced by pregnant mare serum and effects of neonatal androgen in rats.

Authors:  D K Sarkar; G Fink
Journal:  J Endocrinol       Date:  1979-12       Impact factor: 4.286

10.  Estradiol-induced changes in lipoprotein lipase, eating, and body weight in rats.

Authors:  I Ramirez
Journal:  Am J Physiol       Date:  1981-05
View more
  8 in total

Review 1.  Prodrug approaches for CNS delivery.

Authors:  Jarkko Rautio; Krista Laine; Mikko Gynther; Jouko Savolainen
Journal:  AAPS J       Date:  2008-02-05       Impact factor: 4.009

2.  10β,17α-Dihydroxyestra-1,4-dien-3-one: A Bioprecursor Prodrug Preferentially Producing 17α-Estradiol in the Brain for Targeted Neurotherapy.

Authors:  Katalin Prokai-Tatrai; Vien Nguyen; Laszlo Prokai
Journal:  ACS Chem Neurosci       Date:  2018-06-05       Impact factor: 4.418

3.  "All in the mind"? Brain-targeting chemical delivery system of 17β-estradiol (Estredox) produces significant uterotrophic side effect.

Authors:  Katalin Prokai-Tatrai; Szabolcs Szarka; Vien Nguyen; Fatima Sahyouni; Cary Walker; Shastazia White; Tatjana Talamantes; Laszlo Prokai
Journal:  Pharm Anal Acta       Date:  2012

4.  The prodrug DHED selectively delivers 17β-estradiol to the brain for treating estrogen-responsive disorders.

Authors:  Laszlo Prokai; Vien Nguyen; Szabolcs Szarka; Puja Garg; Gauri Sabnis; Heather A Bimonte-Nelson; Katie J McLaughlin; Joshua S Talboom; Cheryl D Conrad; Paul J Shughrue; Todd D Gould; Angela Brodie; Istvan Merchenthaler; Peter Koulen; Katalin Prokai-Tatrai
Journal:  Sci Transl Med       Date:  2015-07-22       Impact factor: 17.956

5.  A redox-based chemical delivery system that enhances estradiol distribution to the brain: disposition studies in the rat.

Authors:  K S Estes; V Keuth; K Dietzel; M E Brewster; N S Bodor; H Derendorf
Journal:  Pharm Res       Date:  1991-09       Impact factor: 4.200

6.  Dose and time-course evaluation of a redox-based estradiol-chemical delivery system for the brain. II. Pharmacodynamic responses.

Authors:  M H Rahimy; J W Simpkins; N Bodor
Journal:  Pharm Res       Date:  1990-11       Impact factor: 4.200

7.  Growth hormone (GH) secretory dynamics in animals administered estradiol utilizing a chemical delivery system.

Authors:  W J Millard; T M Romano; N Bodor; J W Simpkins
Journal:  Pharm Res       Date:  1990-10       Impact factor: 4.200

Review 8.  A Novel Prodrug Approach for Central Nervous System-Selective Estrogen Therapy.

Authors:  Katalin Prokai-Tatrai; Laszlo Prokai
Journal:  Molecules       Date:  2019-11-19       Impact factor: 4.411

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.